BIOMAT Database Logo BIOMAT Database Logo

Design, synthesis, and evaluation of trifluoromethyl ketones as inhibitors of SARS-CoV 3CL protease. 2008

Yi-Ming Shao, and Wen-Bin Yang, and Tun-Hsun Kuo, and Keng-Chang Tsai, and Chun-Hung Lin, and An-Suei Yang, and Po-Huang Liang, and Chi-Huey Wong
Genomics Research Center, Academia Sinica, No. 128, Section 2, Academia Road, Taipei 11529, Taiwan.

A series of trifluoromethyl ketones as SARS-CoV 3CL protease inhibitors was developed. The inhibitors were synthesized in four steps from commercially available compounds. Three different amino acids were explored in the P1-position and in the P2-P4 positions varying amino acids and long alkyl chain were incorporated. All inhibitors were evaluated in an in vitro assay using purified enzyme and fluorogenic substrate peptide. One of the inhibitors showed a time-dependent inhibition, with a K(i) value of 0.3 microM after 4h incubation.

UI MeSH Term Description Entries
D007659 Ketones Organic compounds containing a carbonyl group Ketone
D008745 Methylation Addition of methyl groups. In histo-chemistry methylation is used to esterify carboxyl groups and remove sulfate groups by treating tissue sections with hot methanol in the presence of hydrochloric acid. (From Stedman, 25th ed) Methylations
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D011480 Protease Inhibitors Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES). Antiprotease,Endopeptidase Inhibitor,Endopeptidase Inhibitors,Peptidase Inhibitor,Peptidase Inhibitors,Peptide Hydrolase Inhibitor,Peptide Hydrolase Inhibitors,Peptide Peptidohydrolase Inhibitor,Peptide Peptidohydrolase Inhibitors,Protease Antagonist,Protease Antagonists,Antiproteases,Protease Inhibitor,Antagonist, Protease,Antagonists, Protease,Hydrolase Inhibitor, Peptide,Hydrolase Inhibitors, Peptide,Inhibitor, Endopeptidase,Inhibitor, Peptidase,Inhibitor, Peptide Hydrolase,Inhibitor, Peptide Peptidohydrolase,Inhibitor, Protease,Inhibitors, Endopeptidase,Inhibitors, Peptidase,Inhibitors, Peptide Hydrolase,Inhibitors, Peptide Peptidohydrolase,Inhibitors, Protease,Peptidohydrolase Inhibitor, Peptide,Peptidohydrolase Inhibitors, Peptide
D003546 Cysteine Endopeptidases ENDOPEPTIDASES which have a cysteine involved in the catalytic process. This group of enzymes is inactivated by CYSTEINE PROTEINASE INHIBITORS such as CYSTATINS and SULFHYDRYL REAGENTS.
D006860 Hydrogen Bonding A low-energy attractive force between hydrogen and another element. It plays a major role in determining the properties of water, proteins, and other compounds. Hydrogen Bonds,Bond, Hydrogen,Hydrogen Bond
D000086782 Coronavirus 3C Proteases 3C proteases that occur in species of CORONAVIRIDAE. 3C Proteases, Coronavirus,3C-Like Proteinase, Coronavirus,Chymotrypsin-Like Main Protease, Coronavirus,Coronavirus 3C Proteinases,Coronavirus 3CLpro Proteases,Coronavirus 3CLpro Proteinase,M(pro) Protein, Coronavirus,Main Proteinase, Coronavirus,Mpro Protein, Coronavirus,3C Like Proteinase, Coronavirus,3C Proteinases, Coronavirus,3CLpro Proteases, Coronavirus,3CLpro Proteinase, Coronavirus,Chymotrypsin Like Main Protease, Coronavirus,Coronavirus 3C-Like Proteinase,Coronavirus Main Proteinase,Coronavirus Mpro Protein,Proteinase, Coronavirus 3CLpro,Proteinases, Coronavirus 3C
D014764 Viral Proteins Proteins found in any species of virus. Gene Products, Viral,Viral Gene Products,Viral Gene Proteins,Viral Protein,Protein, Viral,Proteins, Viral
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular

Related Publications

Yi-Ming Shao, and Wen-Bin Yang, and Tun-Hsun Kuo, and Keng-Chang Tsai, and Chun-Hung Lin, and An-Suei Yang, and Po-Huang Liang, and Chi-Huey Wong
Design and synthesis of isatin derivatives as effective SARS-CoV-2 3CL protease inhibitors.
October 2023, Chemical biology & drug design,
Yi-Ming Shao, and Wen-Bin Yang, and Tun-Hsun Kuo, and Keng-Chang Tsai, and Chun-Hung Lin, and An-Suei Yang, and Po-Huang Liang, and Chi-Huey Wong
Synthesis, docking studies, and evaluation of pyrimidines as inhibitors of SARS-CoV 3CL protease.
June 2010, Bioorganic & medicinal chemistry letters,
Yi-Ming Shao, and Wen-Bin Yang, and Tun-Hsun Kuo, and Keng-Chang Tsai, and Chun-Hung Lin, and An-Suei Yang, and Po-Huang Liang, and Chi-Huey Wong
Synthesis of glutamic acid and glutamine peptides possessing a trifluoromethyl ketone group as SARS-CoV 3CL protease inhibitors.
September 2006, Tetrahedron,
Yi-Ming Shao, and Wen-Bin Yang, and Tun-Hsun Kuo, and Keng-Chang Tsai, and Chun-Hung Lin, and An-Suei Yang, and Po-Huang Liang, and Chi-Huey Wong
Design, synthesis and biological evaluation of betulinic acid derivatives as potential inhibitors of 3CL-protease of SARS-CoV-2.
February 2024, Steroids,
Yi-Ming Shao, and Wen-Bin Yang, and Tun-Hsun Kuo, and Keng-Chang Tsai, and Chun-Hung Lin, and An-Suei Yang, and Po-Huang Liang, and Chi-Huey Wong
Structure-based design, synthesis, and evaluation of peptide-mimetic SARS 3CL protease inhibitors.
December 2011, Journal of medicinal chemistry,
Yi-Ming Shao, and Wen-Bin Yang, and Tun-Hsun Kuo, and Keng-Chang Tsai, and Chun-Hung Lin, and An-Suei Yang, and Po-Huang Liang, and Chi-Huey Wong
Design, synthesis, and biological evaluation of novel dipeptide-type SARS-CoV 3CL protease inhibitors: structure-activity relationship study.
July 2013, European journal of medicinal chemistry,
Yi-Ming Shao, and Wen-Bin Yang, and Tun-Hsun Kuo, and Keng-Chang Tsai, and Chun-Hung Lin, and An-Suei Yang, and Po-Huang Liang, and Chi-Huey Wong
Evaluation of metal-conjugated compounds as inhibitors of 3CL protease of SARS-CoV.
September 2004, FEBS letters,
Yi-Ming Shao, and Wen-Bin Yang, and Tun-Hsun Kuo, and Keng-Chang Tsai, and Chun-Hung Lin, and An-Suei Yang, and Po-Huang Liang, and Chi-Huey Wong
Peptidomimetic nitrile warheads as SARS-CoV-2 3CL protease inhibitors.
October 2021, RSC medicinal chemistry,
Yi-Ming Shao, and Wen-Bin Yang, and Tun-Hsun Kuo, and Keng-Chang Tsai, and Chun-Hung Lin, and An-Suei Yang, and Po-Huang Liang, and Chi-Huey Wong
Synthesis and evaluation of isatin derivatives as effective SARS coronavirus 3CL protease inhibitors.
June 2005, Bioorganic & medicinal chemistry letters,
Yi-Ming Shao, and Wen-Bin Yang, and Tun-Hsun Kuo, and Keng-Chang Tsai, and Chun-Hung Lin, and An-Suei Yang, and Po-Huang Liang, and Chi-Huey Wong
Design and synthesis of new tripeptide-type SARS-CoV 3CL protease inhibitors containing an electrophilic arylketone moiety.
January 2013, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!